Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone
acetate when co-administered with prednisone in patients with chemo-naive metastatic
castration resistant prostate Cancer (mCRPC).